FY2029 Earnings Estimate for CLRB Issued By Roth Capital

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Roth Capital issued their FY2029 earnings per share (EPS) estimates for Cellectar Biosciences in a research report issued on Thursday, March 13th. Roth Capital analyst J. Aschoff forecasts that the biopharmaceutical company will earn $0.21 per share for the year. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share.

Several other analysts have also recently issued reports on the stock. StockNews.com assumed coverage on shares of Cellectar Biosciences in a research note on Tuesday. They issued a “sell” rating on the stock. LADENBURG THALM/SH SH started coverage on Cellectar Biosciences in a research report on Thursday, December 5th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, Oppenheimer reissued a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th.

Cellectar Biosciences Trading Up 6.7 %

CLRB stock opened at $0.34 on Monday. The firm has a 50 day moving average of $0.29 and a 200-day moving average of $1.14. The firm has a market capitalization of $15.52 million, a P/E ratio of -0.20 and a beta of 0.96. Cellectar Biosciences has a 12 month low of $0.22 and a 12 month high of $4.17.

Institutional Investors Weigh In On Cellectar Biosciences

Several hedge funds have recently bought and sold shares of CLRB. Oppenheimer & Co. Inc. purchased a new position in Cellectar Biosciences in the 3rd quarter worth approximately $27,000. JPMorgan Chase & Co. lifted its holdings in shares of Cellectar Biosciences by 687.3% during the 4th quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 159,234 shares during the last quarter. Bank of America Corp DE grew its position in Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 41,704 shares in the last quarter. Geode Capital Management LLC increased its stake in Cellectar Biosciences by 3.3% in the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock valued at $754,000 after acquiring an additional 11,266 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Cellectar Biosciences in the fourth quarter valued at $156,000. 16.41% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.